ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $890 | +75.2% | 129,887 | +165.2% | 0.00% | – |
| Q2 2023 | $508 | +31.9% | 48,980 | +3.2% | 0.00% | – |
| Q1 2023 | $385 | -47.7% | 47,468 | +1.6% | 0.00% | – |
| Q4 2022 | $736 | -99.9% | 46,712 | -0.8% | 0.00% | – |
| Q3 2022 | $742,000 | +39.7% | 47,106 | +23.9% | 0.00% | – |
| Q2 2022 | $531,000 | -2.4% | 38,029 | +20.5% | 0.00% | – |
| Q1 2022 | $544,000 | +15.7% | 31,569 | -2.4% | 0.00% | – |
| Q4 2021 | $470,000 | -20.2% | 32,343 | -1.2% | 0.00% | – |
| Q3 2021 | $589,000 | -20.1% | 32,742 | -22.0% | 0.00% | – |
| Q2 2021 | $737,000 | +0.4% | 41,977 | +44.2% | 0.00% | – |
| Q1 2021 | $734,000 | +2058.8% | 29,120 | -7.2% | 0.00% | – |
| Q3 2019 | $34,000 | -50.0% | 31,393 | +0.5% | 0.00% | – |
| Q2 2019 | $68,000 | +7.9% | 31,246 | +199.1% | 0.00% | – |
| Q1 2019 | $63,000 | -99.3% | 10,446 | -96.9% | 0.00% | -100.0% |
| Q3 2017 | $8,784,000 | -20.6% | 340,343 | -16.5% | 0.00% | 0.0% |
| Q2 2017 | $11,058,000 | +7.7% | 407,743 | +18.4% | 0.00% | 0.0% |
| Q1 2017 | $10,268,000 | – | 344,317 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,954,904 | $49,264,000 | 43.26% |
| COMMODORE CAPITAL LP | 1,028,084 | $25,908,000 | 10.32% |
| Foresite Capital Management IV, LLC | 3,399,034 | $85,656,000 | 10.26% |
| VR Adviser, LLC | 3,720,582 | $93,759,000 | 10.17% |
| Parkman Healthcare Partners LLC | 1,709,136 | $43,070,000 | 10.00% |
| Foresite Capital Management V, LLC | 1,258,243 | $31,708,000 | 9.32% |
| Stenahm Asset Managment Ltd | 283,500 | $7,144,000 | 5.04% |
| Samsara BioCapital, LLC | 1,022,612 | $25,770,000 | 4.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 336,737 | $8,486,000 | 4.63% |
| Ghost Tree Capital, LLC | 600,000 | $15,120,000 | 3.55% |